CompletedPHASE2, PHASE3NCT01295112

Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion

Studying Central retinal vein occlusion

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Texas Retina Associates
Principal Investigator
Karl Csaky, MD
Texas Retina Associates
Intervention
Active bevacizumab and Sham dexamethasone(drug)
Enrollment
68 enrolled
Eligibility
18 years · All sexes
Timeline
20112015

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01295112 on ClinicalTrials.gov

Other trials for Central retinal vein occlusion

Additional recruiting or active studies for the same condition.

See all trials for Central retinal vein occlusion

← Back to all trials